Navigation Links
Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association
Date:6/28/2010

JERUSALEM, June 28, 2010 /PRNewswire-FirstCall/ --

- Results of First Exposure of Type I Diabetes Patients to Oramed's Oral Insulin and of a First-in-Humans Study With its Oral GLP-1 Analog

Oramed Pharmaceuticals, Inc. (OTCBB: ORMP) announced today that its executive management is participating in the 2010 Scientific Sessions of the American Diabetes Association currently being held in Orlando, Florida. Dr. Miriam Kidron, Chief Scientific Officer, is scheduled to present results of two of the company's recently completed clinical trials between 12:00 - 2:00 PM ET on Monday, June 28, 2010 in Poster Hall C at the Orange County Convention Center.

One presentation will provide an overview of the results of a Phase IIa study testing the company's flagship ORMD-0801 oral insulin capsule in Type I diabetes patients when administered just before (10-90 minutes) a standard meal. This first exposure of Oramed's oral insulin established the drug's safety and efficacy in Type I diabetics. ORMD-0801 led to a significant increase in insulin levels in 61% of the treatment sessions, irrespective of the time lapse between ORMD-0801 administration and mealtime. The oral insulin preparation effectively kept glucose levels in check in all sessions. These data suggest both tolerance of Oramed's platform to preprandial dosing regimens and its therapeutic potential in regulating Type I diabetes.

In addition, Dr. Kidron will present a summary of Oramed's first-in-humans clinical trial testing the safety and efficacy of ORMD-0901, an encapsulated oral GLP-1 analog formulation. The study monitored t
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
2. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
3. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
4. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
5. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
6. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
7. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
8. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
9. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
10. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
11. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
(Date:1/14/2014)... NineSigma , Inc., the leading innovation partner ... Summit , May 14-16, 2014 at the Global Center ... . This is the premier industry ... achievements through open innovation. Participants will learn how world-changing ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... 21 More than one in three diabetes ... prescribed, stating that they have done so on average three ... estimate that in reality this number could be as high ... and Physicians in Insulin Therapy (GAPP™) survey, released today by ...
... WESTLAKE VILLAGE, Calif., Sept. 21 As consumer ... on overall pharmacy customer satisfaction has increased considerably ... Associates 2010 U.S. National Pharmacy Study(SM) released today. ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20050527/LAF028LOGO-a ) The ...
Cached Medicine Technology:New Global Survey Reveals Over One in Three Patients Fail to Take Insulin as Prescribed 2New Global Survey Reveals Over One in Three Patients Fail to Take Insulin as Prescribed 3J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 2J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 3J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 4J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 5
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/17/2014)... in benign prostate tissue was associated with high-grade, ... found even in those with low prostate-specific antigen ... Cancer Epidemiology, Biomarkers & Prevention , a ... , An analysis of prostate tissue biopsies collected ... the Prostate Cancer Prevention Trial (PCPT) found that ...
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014U.S. military personnel ... "blast plus impact" concussive traumatic brain injury (TBI) ... were evacuated for other medical reasons. Differences in ... and depression 6-12 months after injury are reported ... , a peer-reviewed journal from Mary Ann Liebert, ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2
... Consumer demand for healthy lifestyle drives new store openings, ... new year means,a new resolution or two. For GNC, ... the supplement industry is expected to rise steadily,through 2012, ... time for GNC to once again expand its store ...
... Phase 2 Clinical Trials,Dow AgroSciences CEO Discusses Future Opportunities ... Sangamo BioSciences, Inc.,(Nasdaq: SGMO ) announced that the ... and preview objectives for 2008 during its,annual Investor and ... Jerome Peribere, President and CEO of Dow AgroSciences will ...
... a division of Wyeth (NYSE: WYE ), ... leading scientific and pharmaceutical,achievements at the third annual ... 4. Wyeth received honors for Best Overall Pipeline, ... by Scrip World Pharmaceutical News,a leading source of ...
... -- Apart from a more complicated medical case, ... time with their patients" Researchers at UC Davis ... that affect the length of a patients medical ... the doctors visit. , In a new ...
... Drug has significant risks, and its benefits are still debated, ... U.S. Food and Drug Administration advisory panel recommended Wednesday that ... women with advanced breast cancer. , In a close vote, ... the growth of tumors did not outweigh the increased risk ...
... two Phase III clinical trials support that Asacol, an ... agents known as 5-aminosalicylic acids (5-ASAs), is an effective ... ulcerative colitis (UC), including isolated proctitis. The results ... dosed at 2.4 g/day for six weeks, experienced significant ...
Cached Medicine News:Health News:GNC Franchising Expected to Grow Through 2008 2Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 2Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 3Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 4Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 5Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 6Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 7Health News:Wyeth Receives Honors at the 2007 Scrip Awards 2Health News:Wyeth Receives Honors at the 2007 Scrip Awards 3Health News:Wyeth Receives Honors at the 2007 Scrip Awards 4Health News:Wyeth Receives Honors at the 2007 Scrip Awards 5Health News:New UC Davis study finds physician style and HMO affiliation impact lengths of patient visit 2Health News:FDA Panel Says No to Avastin for Advanced Breast Cancer 2Health News:FDA Panel Says No to Avastin for Advanced Breast Cancer 3Health News:Asacol treats UC symptoms of isolated proctitis 2
... (PNET) is the foundation and supporting ... systems. This extremely versatile software supports ... for all the GI diagnostic testing ... and catheter-based ambulatory pH testing, esophageal ...
Symbia T, a TruePoint SPECTCT system, combines a dual-detector variable angle gamma camera with a CT scanner optimized for rapid, accurate attenuation correction of the nuclear data....
... STAT analyzer and data management system ... meet the traditional needs of data management ... for the management of STAT analyzer systems., ... simple connectivity solution for both STAT analyzers ...
... Enterprise is a comprehensive IT solution ... from admission to follow-up. This scalable ... and diagnostic tools from syngo Dynamics ... single, longitudinal clinical repository that becomes ...
Medicine Products: